Navigation Links
Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
Date:2/11/2008

FREDERICK, Md., Feb. 11 /PRNewswire/ -- Cancer research pioneer Michael G. Hanna Jr. Ph.D., also Vaccinogen, Inc.'s Founder, Chairman and CEO has acquired the rights to OncoVAX(R), a vaccine with the potential to prevent colon cancer from recurring in many patients.

"This agreement represents a major step forward in defeating cancer by increasing the body's immunity to it," said Dr. Hanna, who has been working on cancer vaccines for more than 30 years.

In the agreement, Vaccinogen obtained exclusive license to OncoVAX(R) Active Specific Immunotherapy as well as an important component of the product TICE BCG. The vaccine is made from the patients' own tumor and is injected back into the patient to effect an immune response against recurrence of that cancer.

The FDA views Stage II colon cancer as an unmet medical need. When colon cancer recurs after surgery it is frequently fatal. OncoVAX(R) prevents that recurrence and thereby reduces recurrence and deaths by over 50%. Vaccinogen is currently preparing to commercialize the vaccine in Switzerland.

About OncoVAX(R)

OncoVAX(R) immunotherapy is based on a decades-long attempt by scientists to transform the body's immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases. Immune stimulation should be able to create a population of white blood cells that can kill tumor cells wherever they arise in the body, years after surgical removal of the original tumor.

Vaccinogen's scientists prepare a vaccine from the patient's own tumor. The cells are dissociated, irradiated to make them non-tumorigenic and administered to the patient by three weekly injections, starting four weeks after surgery. A booster vaccination is administered six months later.

About Vaccinogen

Vaccinogen is a biopharmaceutical company developing and commercializing canc
'/>"/>

SOURCE Vaccinogen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Calif. , July 29, 2015 Daiichi ... Daiichi Sankyo Group, announced today that The New ... results demonstrating that the investigational drug, PLX3397, an oral ... patients with tenosynovial giant cell tumor (TGCT), a rare, ... Following phase 1 dose-escalation, which evaluated the ...
(Date:7/29/2015)... MONROVIA, Calif., July 29, 2015  STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today reported ... Second Quarter Overview , Net Sales ... , Unfavorable Currency Impact of $2.1 Million from the ... in EMEA and 13% in China , APAC Sales ...
(Date:7/29/2015)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced ... June 30, 2015. "We are impressed with ... Mihael H. Polymeropoulos M.D., Vanda,s President and CEO, "further ... our products set the stage for the next level ... , Total net product sales for the second ...
Breaking Medicine Technology:Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9
... May 7 Shire plc (LSE: SHP,Nasdaq: ... findings from a new data analysis that ... (methylphenidate transdermal,system) between boys and girls aged ... Disorder (ADHD). The findings from the analysis ...
... III Data Presented at American Psychiatric Association Annual ... Inc.,(NYSE: FRX ) announced today that study ... depression as compared to,placebo treatment and was well ... (MDD), according to phase III data presented at,the ...
Cached Medicine Technology:New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 2Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 3Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 4Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 5Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 6
(Date:7/29/2015)... ... 2015 , ... Potomac Pilates, an elite Washington, D.C. metro area-based Pilates studio, ... ® by Potomac Pilates. On Thursday, July 30, Potomac Pilates will unveil its ... Potomac Pilates will continue to offer the same classes and personal experiences their clients ...
(Date:7/29/2015)... ... ... Join Luz Delia Gerber and Abbi Ferrin as they share their empowering ... the body actually works. A state of mindfulness allows one to be present and ... to forge this new relationship with their bodies. , Abi Ferrin has a passion ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... autism. Parents, educators and service providers of children living with autism will converge ... serve the growing demographic. , The National Autism Conference will be held ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... type, component, delivery model, application, end user and region. Factors such as the ... awareness about benefits of analytics, and increase in venture capital investments are driving ...
(Date:7/29/2015)... MOUNT LAUREL, NJ (PRWEB) , ... July 29, ... ... Manager Certification’s (the Commission) CCM® credential for a five-year period, expiring November 30, ... of its CCM credential by submitting an application demonstrating the program’s compliance with ...
Breaking Medicine News(10 mins):Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Pampering and Empowerment Abound at Final Event in Luz Delia Gerber’s Book Unveiling 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3
... fertility may be making it even harder for couples to ... countries, reveals a new European Science Foundation (ESF) report launching ... infertile, contributing to the growing demand for assisted reproduction techniques ... Edwards won the Nobel Prize in Medicine last month. ...
... The number of people infected with HIV/AIDS in ... for treatment by the end of the decade, forcing ... allocate inadequate supplies of lifesaving antiretroviral therapy (ART), says ... It calls for a renewed emphasis on reducing the ...
... Gordon HealthDay Reporter , FRIDAY, Nov. 26 (HealthDay ... type 1 diabetes, according to a new study. , ... have an even lower mortality rate compared with those diagnosed ... good [diabetes] control, you can have a near-normal life expectancy," ...
... reports that the use of computed tomography (CT) in the ... continues, by 2011, nearly 20 percent of all emergency department ... this study were presented today at the annual meeting of ... and in the journal Radiology. "It is not ...
... with a personal history of breast cancer should consider ... to a study presented today at the annual meeting ... The American Cancer Society (ACS) guidelines currently recommend annual ... gene mutation or with a strong family history indicating ...
... 28 (HealthDay News) -- The contents of school vending machines ... study shows. U.S. researchers examined the impact that vending ... at 152 schools. The vending machines in 83 percent of ... sodas and sweets. In elementary schools that sold fruits ...
Cached Medicine News:Health News:Male reproductive problems may add to falling fertility rates 2Health News:Number of HIV/AIDS cases in sub-Saharan Africa expected to greatly outpace resources 2Health News:Number of HIV/AIDS cases in sub-Saharan Africa expected to greatly outpace resources 3Health News:Type 1 Diabetes Death Rate is Falling, But Not Fast Enough 2Health News:Type 1 Diabetes Death Rate is Falling, But Not Fast Enough 3Health News:Emergency departments see substantial increase in CT exams 2Health News:Women with personal history of breast cancer should be screened with MRI 2
... Systems Orthokeratology (oprifocon A) Contact Lenses ... used for orthokeratology, a process that ... wears these lenses overnight and removes ... day, nearsightedness is temporarily corrected or ...
... a way to help your patients with ... Based on the outcomes of several ... has improved the quality of their lives; ... activities of daily living. , ,MedCath Diagnostics, ...
... 300 ,Oblique 45, ,Type 330 ,Straight, ... by setting the illumination between lenses ... ideal for use in ophthalmology and ... conventional compact microscope can; an advanced ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
Medicine Products: